18 results
425
EX-99.2
INFIQ
Infinity Pharmaceuticals, Inc.
20 Jun 23
Business combination disclosure
8:02am
cells need significant amounts of energy to grow, and can switch between mitochondria and glycolytic metabolic pathways to escape the blocking of either … Proof of Concept of ME-344 as a Novel Mitochondrial Inhibitor with the Potential to Prevent Anti-Angiogenic Escape in Combination with Bevacizumab 79
8-K
EX-99.2
INFIQ
Infinity Pharmaceuticals, Inc.
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
cells need significant amounts of energy to grow, and can switch between mitochondria and glycolytic metabolic pathways to escape the blocking of either … Proof of Concept of ME-344 as a Novel Mitochondrial Inhibitor with the Potential to Prevent Anti-Angiogenic Escape in Combination with Bevacizumab 79
8-K
EX-10.8
INFIQ
Infinity Pharmaceuticals, Inc.
18 Sep 06
Infinity Pharmaceuticals Announces Completion of Merger with Discovery Partners International
12:00am
the presence on or under or the escape, seepage, leakage, spillage, discharge, emission or release of any Hazardous Materials on the premises owned
424B4
INFIQ
Infinity Pharmaceuticals, Inc.
6 May 04
Prospectus supplement with pricing info
12:00am
of it without allowing the compound being synthesized inside to escape. In this way, we can process tens, hundreds or even thousands of micro
424A
n39qup64ca bcd2fuwu
15 Apr 04
Prospectus with significant changes
12:00am
S-3
o5up m9c4eblk
10 Mar 04
Shelf registration
12:00am
10-K
rhiy 9a3sqr4j
29 Mar 02
Annual report
12:00am
10-K405
kxcvlas 63u91wm
27 Mar 01
Annual report (delinquent filer disclosure)
12:00am
424B4
ubxjuebbl3ar
28 Jul 00
Prospectus supplement with pricing info
12:00am
S-1/A
1lgd9li
23 Jun 00
IPO registration (amended)
12:00am
S-1
5w2hb610mrfgqi
9 May 00
IPO registration
12:00am
- Prev
- 1
- Next